Transgene ends third-quarter with €25.1 million

By Lisa Kerner

Charlotte, N.C., Oct. 11 - Transgene SA said it had cash, cash equivalents and short-term investments totaling €25.1 million on Sept. 30.

The Strasbourg, France, biopharmaceutical company reported net cash expenditures for the nine months ended Sept. 30 of €15.9 million, not including proceeds from the exercise of warrants and stock options, compared with €15.3 million for the first nine months of 2005.

Transgene raised €14.3 million through the exercise of warrants issued as part of the July 2005 capital increase.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.